Amazon Pharmacy (NASDAQ:AMZN) said it has begun offering Eli Lilly’s Zepbound KwikPen, a multi-dose injectable medication for weight management, with cash-pay pricing starting at $299 per month for the 2.5 mg introductory dose, according to a company press release. The offering further expands Amazon’s growing presence in healthcare as the $2.29 trillion company continues broadening its reach within the Broadline Retail sector.
The Zepbound KwikPen provides a full month of treatment in a single injection device, designed to replace multiple single-dose pens. Customers with valid prescriptions can place orders through Amazon Pharmacy and have the medication delivered directly to their homes.
Zepbound is approved for adult weight management when used alongside diet and exercise and is also authorized for treating adults with obesity and moderate-to-severe obstructive sleep apnea. It has become one of the most widely prescribed injectable treatments for weight management in the United States.
Amazon Pharmacy currently offers same-day delivery to more than half of U.S. households and gives customers 24/7 access to licensed pharmacists. The platform automatically applies manufacturer-sponsored coupons at checkout, and customers have collectively saved more than $200 million through the program. GLP-1 medications account for the largest portion of those savings.
The expansion of Amazon’s pharmacy services comes as the company trades at a P/E ratio of 29.83 while generating $716.92 billion in revenue with growth of 12.38%. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. Investors can access more detailed analysis through InvestingPro’s Pro Research Report, which covers Amazon along with more than 1,400 U.S. equities and translates complex Wall Street data into practical insights.
“By expanding access to the Zepbound KwikPen with upfront self-pay pricing, we’re making it easier for customers to get the treatments their doctors prescribe in a simpler way—delivered directly and reliably to their homes,” said Tanvi Patel, Vice President and General Manager of Amazon Pharmacy.
Amazon Pharmacy has been distributing GLP-1 medications since 2021 and collaborates with healthcare providers and digital health platforms including LillyDirect, WeightWatchers, UpScriptHealth and Noom.
The service accepts most insurance plans and provides free two-day delivery for Prime members. Same-day delivery is currently available in nearly 3,000 cities and towns, with plans to expand coverage to roughly 4,500 locations by the end of 2026.
In other developments
Amazon.com Inc. recently introduced Amazon Connect Health, an AI-driven platform designed to reduce administrative burdens for healthcare providers and patients. The system automates tasks such as identity verification, appointment scheduling and medical coding while integrating with electronic health record systems.
Separately, BofA Securities reaffirmed its Buy rating on Amazon shares, citing strong growth at Anthropic as a potential catalyst for improving sentiment toward Amazon Web Services. Anthropic’s annualized revenue run rate has increased rapidly, fueled by demand for its AI models and developer tools.
Amazon has also reduced headcount within its robotics division as part of a broader restructuring effort that has eliminated more than 57,000 corporate roles since late 2022. Despite the layoffs, the company said robotics remains a core strategic priority.
At the same time, Amazon is involved in ongoing discussions with Anthropic investors regarding a dispute with the Pentagon over the use of artificial intelligence technologies. CEO Andy Jassy is reportedly participating in those talks.
In addition, Amazon and several other technology companies have pledged to manage the power consumption of AI data centers in response to public concerns about rising electricity costs associated with expanding AI infrastructure.